Cargando…

Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature

Background The presence of metabolic syndrome (MS) is associated with increased disease severity in patients with coronavirus disease 2019 (COVID-19). Non-alcoholic fatty liver disease (NAFLD) associated with or without MS may be related to increased morbidity and mortality in COVID-19, but large In...

Descripción completa

Detalles Bibliográficos
Autores principales: Nath, Preetam, Kumar, Raj, Mallick, Bipadabhanjan, Das, Swati, Anand, Anil, Panigrahi, Sarat C, Duseja, Ajay, Acharya, Subrat K, Chawla, Yogesh K, Praharaj, Dibya L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358152/
https://www.ncbi.nlm.nih.gov/pubmed/35949776
http://dx.doi.org/10.7759/cureus.26683
_version_ 1784763871647498240
author Nath, Preetam
Kumar, Raj
Mallick, Bipadabhanjan
Das, Swati
Anand, Anil
Panigrahi, Sarat C
Duseja, Ajay
Acharya, Subrat K
Chawla, Yogesh K
Praharaj, Dibya L
author_facet Nath, Preetam
Kumar, Raj
Mallick, Bipadabhanjan
Das, Swati
Anand, Anil
Panigrahi, Sarat C
Duseja, Ajay
Acharya, Subrat K
Chawla, Yogesh K
Praharaj, Dibya L
author_sort Nath, Preetam
collection PubMed
description Background The presence of metabolic syndrome (MS) is associated with increased disease severity in patients with coronavirus disease 2019 (COVID-19). Non-alcoholic fatty liver disease (NAFLD) associated with or without MS may be related to increased morbidity and mortality in COVID-19, but large Indian studies are lacking. The present study was carried out to assess the impact of NAFLD on the clinical outcomes in patients with COVID-19 infection. Methods All patients with COVID-19 hospitalized at a tertiary care hospital in eastern India from April 4 to December 31, 2020, were included in the study. Patients who underwent non-contrast CT (NCCT) chest were evaluated for the presence of hepatic steatosis based on a validated criterion liver attenuation (HU) value lower than the spleen, absolute liver attenuation lower than 40 HU, and liver to spleen attenuation ratio less than 1. Patients were divided into two groups, those with or without fatty liver. Baseline characteristics including age, sex, liver function tests, and outcomes including duration of hospital stay and mortality were compared. Results A total of 6003 COVID-19-positive patients were admitted during the study period. Of these patients, 214 children (<18 years) with COVID-19 infection were excluded. One hundred and eight patients with a history of significant ethanol abuse were excluded from the analysis. NCCT scan was not done in 1698 patients. Finally, 3983 patients were included in the study. They were divided into two groups depending on the presence or absence of NAFLD. Of the 3983 patients, 814 (20.4%) had NAFLD. Overall in-hospital mortality among the study group was 6.4%. The mortality rate among patients with NAFLD was 6.7% while that in patients without fatty liver was 6% (P=0.381). Similarly, the mean duration of hospital stay was also comparable between both the groups (10.63±7.2days vs 10.65±6.6 days;P=0.66). Prevalence of NAFLD was similar in survivors and non-survivors; 759 of 2981 patients (25.4%) and 55 of 188 patients 29.2% (P=0.381), respectively. On univariate analysis, male sex, older age, elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) along with low serum albumin and low absolute eosinophil counts (AEC) were associated with higher mortality. However, on multivariate analysis, only older age, male sex, and low albumin levels were associated with higher mortality. Surprisingly, a sub-group analysis showed that females without NAFLD were at a higher risk of mortality than those with fatty liver (4.9% vs 12.3%; P=0.006). Similarly, patients with lower AST levels had higher mortality compared to patients with significantly elevated AST levels (more than two times the upper limit of normal (ULN)), irrespective of the presence of fatty liver. Conclusions The prevalence of fatty liver in severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infected patients is similar to the general population in India, the presence of which is not a predictor of severe disease. However, mortality is higher in males and elderly patients.
format Online
Article
Text
id pubmed-9358152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-93581522022-08-09 Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature Nath, Preetam Kumar, Raj Mallick, Bipadabhanjan Das, Swati Anand, Anil Panigrahi, Sarat C Duseja, Ajay Acharya, Subrat K Chawla, Yogesh K Praharaj, Dibya L Cureus Radiology Background The presence of metabolic syndrome (MS) is associated with increased disease severity in patients with coronavirus disease 2019 (COVID-19). Non-alcoholic fatty liver disease (NAFLD) associated with or without MS may be related to increased morbidity and mortality in COVID-19, but large Indian studies are lacking. The present study was carried out to assess the impact of NAFLD on the clinical outcomes in patients with COVID-19 infection. Methods All patients with COVID-19 hospitalized at a tertiary care hospital in eastern India from April 4 to December 31, 2020, were included in the study. Patients who underwent non-contrast CT (NCCT) chest were evaluated for the presence of hepatic steatosis based on a validated criterion liver attenuation (HU) value lower than the spleen, absolute liver attenuation lower than 40 HU, and liver to spleen attenuation ratio less than 1. Patients were divided into two groups, those with or without fatty liver. Baseline characteristics including age, sex, liver function tests, and outcomes including duration of hospital stay and mortality were compared. Results A total of 6003 COVID-19-positive patients were admitted during the study period. Of these patients, 214 children (<18 years) with COVID-19 infection were excluded. One hundred and eight patients with a history of significant ethanol abuse were excluded from the analysis. NCCT scan was not done in 1698 patients. Finally, 3983 patients were included in the study. They were divided into two groups depending on the presence or absence of NAFLD. Of the 3983 patients, 814 (20.4%) had NAFLD. Overall in-hospital mortality among the study group was 6.4%. The mortality rate among patients with NAFLD was 6.7% while that in patients without fatty liver was 6% (P=0.381). Similarly, the mean duration of hospital stay was also comparable between both the groups (10.63±7.2days vs 10.65±6.6 days;P=0.66). Prevalence of NAFLD was similar in survivors and non-survivors; 759 of 2981 patients (25.4%) and 55 of 188 patients 29.2% (P=0.381), respectively. On univariate analysis, male sex, older age, elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) along with low serum albumin and low absolute eosinophil counts (AEC) were associated with higher mortality. However, on multivariate analysis, only older age, male sex, and low albumin levels were associated with higher mortality. Surprisingly, a sub-group analysis showed that females without NAFLD were at a higher risk of mortality than those with fatty liver (4.9% vs 12.3%; P=0.006). Similarly, patients with lower AST levels had higher mortality compared to patients with significantly elevated AST levels (more than two times the upper limit of normal (ULN)), irrespective of the presence of fatty liver. Conclusions The prevalence of fatty liver in severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infected patients is similar to the general population in India, the presence of which is not a predictor of severe disease. However, mortality is higher in males and elderly patients. Cureus 2022-07-09 /pmc/articles/PMC9358152/ /pubmed/35949776 http://dx.doi.org/10.7759/cureus.26683 Text en Copyright © 2022, Nath et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiology
Nath, Preetam
Kumar, Raj
Mallick, Bipadabhanjan
Das, Swati
Anand, Anil
Panigrahi, Sarat C
Duseja, Ajay
Acharya, Subrat K
Chawla, Yogesh K
Praharaj, Dibya L
Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title_full Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title_fullStr Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title_full_unstemmed Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title_short Effect of Nonalcoholic Fatty Liver Disease (NAFLD) on COVID-19: A Single-Center Study of 3983 Patients With Review of Literature
title_sort effect of nonalcoholic fatty liver disease (nafld) on covid-19: a single-center study of 3983 patients with review of literature
topic Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358152/
https://www.ncbi.nlm.nih.gov/pubmed/35949776
http://dx.doi.org/10.7759/cureus.26683
work_keys_str_mv AT nathpreetam effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT kumarraj effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT mallickbipadabhanjan effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT dasswati effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT anandanil effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT panigrahisaratc effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT dusejaajay effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT acharyasubratk effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT chawlayogeshk effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature
AT praharajdibyal effectofnonalcoholicfattyliverdiseasenafldoncovid19asinglecenterstudyof3983patientswithreviewofliterature